Private Advisor Group LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Private Advisor Group LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 25.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,879 shares of the medical equipment provider's stock after purchasing an additional 2,822 shares during the period. Private Advisor Group LLC's holdings in Zimmer Biomet were worth $1,466,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after buying an additional 125,852 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the period. Hotchkis & Wiley Capital Management LLC grew its position in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock valued at $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Zimmer Biomet by 0.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider's stock valued at $108,621,000 after purchasing an additional 4,388 shares during the period. Finally, FMR LLC lifted its holdings in Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider's stock worth $80,999,000 after purchasing an additional 162,384 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 0.3 %

NYSE:ZBH traded up $0.27 during trading hours on Friday, reaching $104.32. The company's stock had a trading volume of 2,813,620 shares, compared to its average volume of 1,900,642. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm has a market capitalization of $20.77 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 1.95 and a beta of 1.02. The firm has a 50-day simple moving average of $105.72 and a 200-day simple moving average of $107.37. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ZBH shares. JMP Securities reiterated a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.